Table 1.

Distribution of clinical and demographic features across three cohorts. Features were from 546 cervical cancer patients combined from the USA, China, and Uganda cohorts. Note: NA means either the patient did not give the information or it was not measured (missing).

Cervical Cancer Stage	I	II	III	III/IV	IV	NA
	225	178	83	42	10	8
Histology	Adenocarcinoma	Adenosquamous	Neuroendocrine	Squamous	Undifferentiated	NA
	51	16	2	387	1	89
Cancer Grade	G1	G2	G3	G4	NA
	21	176	113	3	233
HPV Status	Negative	Positive	NA
	11	391	144
HPV Type	HPV16	HPV18	HPV26	HPV30	HPV31	HPV33	HPV34	HPV35
	220	62	1	2	11	9	1	2
	HPV39	HPV45	HPV51	HPV52	HPV56	HPV58	HPV59	HPV6
	3	29	1	13	2	14	6	1
	HPV66	HPV68	HPV69	HPV70	HPV73	HPV82	HPV9	Negative	NA
	2	3	2	1	2	3	1	11	144
HPV Clade	A5	A6	A7	A9	A11	Negative	Other	NA
	1	2	104	269	1	11	14	144
HPV Integration	Non-integrated	Productive integrated	Silent integrated	NA
	54	315	25	152
HIV Status	Negative	Positive	NA
	122	89	335
Age Range	21–30	31–40	41–50	51–60	61–70	71–80	81–90	NA
	29	111	174	145	59	22	5	1
Age Stat	Min.	1st Qu.	Median	Mean	3rd Qu.	Max.	NA
	21	40.24	48	49.01	56.71	89	1
Race	Alaska Native	Asian	Black	White	NA
	8	125	231	163	19
Cohort (Region)	TCGA (USA)	MOCC (China)	HTMCP (Uganda)
	228	106	212